<DOC>
	<DOC>NCT01820091</DOC>
	<brief_summary>To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®</brief_title>
	<detailed_description>This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm, Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>At least 18 years of age Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) after at least one line of therapy Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Histologically or cytologically confirmed Stage III B/IV NSCLC Adequate hematological, hepatic, and renal function Available during the first 8 weeks of the study treatment period to visit the clinic for oral Mucositis assessments on scheduled days Active concurrent malignancy. If there is a history of prior malignancies other than those exceptions listed above, the patient must be diseasefree for at least 5 years Congestive heart failure Uncontrolled hypertension Known human immunodeficiency virus (HIV)positive diagnosis Previous exposure to Pralatrexate Pregnant or breastfeeding women Major surgery within 14 days of enrollment Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment Symptomatic central nervous system (CNS) metastases or lesions for which treatment is required. Patients who received prophylactic CNS treatment are eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>